Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.

Published on Jan 25, 2018in Cell38.637
· DOI :10.1016/J.CELL.2018.01.006
Matthew R. Janes5
Estimated H-index: 5
,
Jingchuan Zhang3
Estimated H-index: 3
+ 31 AuthorsYi Liu26
Estimated H-index: 26
Sources
Abstract
Summary KRAS G12C was recently identified to be potentially druggable by allele-specific covalent targeting of Cys-12 in vicinity to an inducible allosteric switch II pocket (S-IIP). Success of this approach requires active cycling of KRAS G12C between its active-GTP and inactive-GDP conformations as accessibility of the S-IIP is restricted only to the GDP-bound state. This strategy proved feasible for inhibiting mutant KRAS in vitro ; however, it is uncertain whether this approach would translate to  in vivo . Here, we describe structure-based design and identification of ARS-1620, a covalent compound with high potency and selectivity for KRAS G12C . ARS-1620 achieves rapid and sustained in vivo target occupancy to induce tumor regression. We use ARS-1620 to dissect oncogenic KRAS dependency and demonstrate that monolayer culture formats significantly underestimate KRAS dependency in vivo . This study provides in vivo evidence that mutant KRAS can be selectively targeted and reveals ARS-1620 as representing a new generation of KRAS G12C -specific inhibitors with promising therapeutic potential.
References55
Newest
#1E. Robert McDonald (Novartis)H-Index: 12
#2Antoine de Weck (Novartis)H-Index: 5
Last. William R. SellersH-Index: 121
view all 100 authors...
Summary Elucidation of the mutational landscape of human cancer has progressed rapidly and been accompanied by the development of therapeutics targeting mutant oncogenes. However, a comprehensive mapping of cancer dependencies has lagged behind and the discovery of therapeutic targets for counteracting tumor suppressor gene loss is needed. To identify vulnerabilities relevant to specific cancer subtypes, we conducted a large-scale RNAi screen in which viability effects of mRNA knockdown were ass...
295 CitationsSource
#1Mike Selby (Leidos)H-Index: 1
#2Rene Delosh (Leidos)H-Index: 4
Last. David Evans (Leidos)H-Index: 5
view all 11 authors...
The NCI60 cell line panel screen includes 60 human tumor cell lines derived from nine tumor types that has been used over the past 20+ years to screen small molecules, biologics, and natural products for activity. Cells in monolayer culture in 96-well plates are exposed to compounds for 48 h, and Sulforhodamine B is used to determine cell viability. Data analysis tools such as COMPARE allow classification of compounds based on the pattern of cell line response. However, many compounds highly act...
14 CitationsSource
#1Matthew Welsch (Columbia University)H-Index: 7
#2Anna Kaplan (Columbia University)H-Index: 7
Last. Brent R. Stockwell (Columbia University)H-Index: 76
view all 20 authors...
Design of small molecules that disrupt protein-protein interactions, including the interaction of RAS proteins and their effectors, may provide chemical probes and therapeutic agents. We describe here the synthesis and testing of potential small-molecule pan-RAS ligands, which were designed to interact with adjacent sites on the surface of oncogenic KRAS. One compound, termed 3144, was found to bind to RAS proteins using microscale thermophoresis, nuclear magnetic resonance spectroscopy, and iso...
125 CitationsSource
#1Adrian Vallejo (University of Navarra)H-Index: 4
#2Naiara Perurena (University of Navarra)H-Index: 9
Last. S. Vicent (University of Navarra)H-Index: 1
view all 23 authors...
KRAS-driven cancers remain refractory to current clinical therapies. In this study, the authors show that lung and pancreatic cancers expressing oncogenic KRAS can be targeted by genetic inhibition of FOSL1, which involves downregulation of genes of the mitotic machinery.
55 CitationsSource
#1Yuan Xiong (Harvard University)H-Index: 7
#2Jia Lu (UTD: University of Texas at Dallas)H-Index: 1
Last. Nathanael S. Gray (Harvard University)H-Index: 121
view all 12 authors...
Ras proteins are members of a large family of GTPase enzymes that are commonly mutated in cancer where they act as dominant oncogenes. We previously developed an irreversible guanosine-derived inhibitor, SML-8-73-1, of mutant G12C RAS that forms a covalent bond with cysteine 12. Here we report exploration of the structure–activity relationships (SAR) of hydrolytically stable analogues of SML-8-73-1 as covalent G12C KRAS inhibitors. We report the discovery of difluoromethylene bisphosphonate anal...
41 CitationsSource
The clinical and commercial success of covalent drugs has prompted a renewed and more deliberate pursuit of covalent and irreversible mechanisms within drug discovery. A covalent mechanism can produce potent inhibition in a biochemical, cellular, or in vivo setting. In many cases, teams choose to focus on the consequences of the covalent event, defined by an IC50 value. In a biochemical assay, the IC50 may simply reflect the target protein concentration in the assay. What has received less atten...
54 CitationsSource
#1Emmet Jordan (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 16
#2Hyunjae R. Kim (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 10
Last. Gregory J. Riely (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 104
view all 36 authors...
Tumor genetic testing is standard of care for patients with advanced lung adenocarcinoma but the fraction of patients who derive clinical benefit remains undefined. Here, we report the experience of 860 patients with metastatic lung adenocarcinoma analyzed prospectively for mutations in >300 cancer-associated genes. Potentially actionable genetic events were stratified into one of four levels based upon published clinical or laboratory evidence that the mutation in question confers increased sen...
222 CitationsSource
#1Jonathan M. L. Ostrem (Brigham and Women's Hospital)H-Index: 1
#2Kevan M. Shokat (UCSF: University of California, San Francisco)H-Index: 130
KRAS is one of the most frequently activated proteins in cancer, yet the development of RAS inhibitors has proven to be extremely challenging. Here, Shokat and Ostrem discuss the latest insights into RAS structure and dynamics, consider potential mechanisms of action for effective RAS inhibitors, and examine recent reports of direct RAS inhibitors.
214 CitationsSource
#1Joshua D. Campbell (Broad Institute)H-Index: 26
#2Anton Alexandrov (WashU: Washington University in St. Louis)H-Index: 6
Last. Matthew Meyerson (Broad Institute)H-Index: 191
view all 30 authors...
Matthew Meyerson, Ramaswamy Govindan and colleagues examine the exome sequences and copy number profiles of 660 lung adenocarcinoma and 484 lung squamous cell carcinoma tumors. They identify novel significantly mutated genes and amplification peaks and find that around half of the tumors have at least five predicted neoepitopes.
487 CitationsSource
#1Marios Giannakis (Broad Institute)H-Index: 31
#2Xinmeng Jasmine Mu (Broad Institute)H-Index: 28
Last. Levi A. Garraway (Broad Institute)H-Index: 129
view all 30 authors...
Large-scale genomic characterization of tumors from prospective cohort studies may yield new insights into cancer pathogenesis. We performed whole-exome sequencing of 619 incident colorectal cancers (CRCs) and integrated the results with tumor immunity, pathology, and survival data. We identified recurrently mutated genes in CRC, such as BCL9L, RBM10, CTCF, and KLF5, that were not previously appreciated in this disease. Furthermore, we investigated the genomic correlates of immune-cell infiltrat...
436 CitationsSource
Cited By330
Newest
#2Wen-Wen Peng (JXAU: Jiangxi Agricultural University)
Last. Jian-Ping Huang (JXAU: Jiangxi Agricultural University)H-Index: 1
view all 5 authors...
Source
#1Yifeng Xia (BMS: Bristol-Myers Squibb)
#2Xiaodong Ji (BMS: Bristol-Myers Squibb)
Last. Gang Lu (BMS: Bristol-Myers Squibb)H-Index: 21
view all 0 authors...
The multiplexed cancer cell line screening platform PRISM demonstrated its utility in testing hundreds of cell lines in a single run, possessing the potential to speed up anti-cancer drug discovery, validation and optimization. Here we described the development and implementation of a next-generation PRISM platform combining Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9-mediated gene editing, cell line DNA barcoding and next-generation sequencing to enable genetic and/o...
Source
#1Katarzyna Z Haza (University of Leeds)H-Index: 1
#2Heather L. Martin (University of Leeds)H-Index: 8
Last. Modupe Ajayi (University of Leeds)H-Index: 1
view all 0 authors...
RAS mutations are the most common oncogenic drivers across human cancers, but there remains a paucity of clinically-validated pharmacological inhibitors of RAS, as druggable pockets have proven difficult to identify. Here, we identify two RAS-binding Affimer proteins, K3 and K6, that inhibit nucleotide exchange and downstream signaling pathways with distinct isoform and mutant profiles. Affimer K6 binds in the SI/SII pocket, whilst Affimer K3 is a non-covalent inhibitor of the SII region that re...
Source
Last. Hart T
view all 0 authors...
Coessentiality networks derived from CRISPR screens in cell lines provide a powerful framework for identifying functional modules in the cell and for inferring the role of uncharacterized genes. However, these networks integrate signal across all underlying data, and can mask strong interactions that occur in only a subset of the cell lines analyzed. Here we decipher dynamic functional interactions by identifying significant cellular contexts, primarily by oncogenic mutation, lineage, and tumor ...
Source
#1Alexios Chatzigoulas (UoA: National and Kapodistrian University of Athens)H-Index: 2
#2Zoe Cournia (Academy of Athens)H-Index: 23
1 CitationsSource
#1Baoyuan Zhang (SJTU: Shanghai Jiao Tong University)
#2Yan Zhang (SJTU: Shanghai Jiao Tong University)H-Index: 5
Last. Ruibao Ren (SJTU: Shanghai Jiao Tong University)H-Index: 4
view all 0 authors...
KRAS mutation is one of the most prevalent genetic drivers of cancer development, yet KRAS mutations are until very recently considered undruggable. There are ongoing trials of drugs that target the KRAS G12C mutation, yet acquired drug resistance from the extended use has already become a major concern. Here, it is demonstrated that KRAS G12C inhibition induces sustained activation of focal adhesive kinase (FAK) and show that a combination therapy comprising KRAS G12C inhibition and a FAK inhib...
Source
#1Okutachi S (University of Luxembourg)
#2Manoharan Gb (University of Luxembourg)
Last. Daniel Abankwa (University of Luxembourg)H-Index: 21
view all 0 authors...
Phenothiazines (PTZ) are well known as inhibitors of monoamine neurotransmitter receptors, notably dopamine receptors. Because of this activity they are used for decades as antipsychotic drugs. In addition, significant anti-cancer properties have been ascribed to them. Several attempts for their repurposing were made, however, their incompletely understood polypharmacology is challenging. Here we examined the potential of PTZ to synergistically act on two cancer associated targets, calmodulin (C...
Source
The central protein in the oncogenic circuitry is the Ras GTPase that has been under intense scrutiny for the last four decades. From its discovery as a viral oncogene and its non–oncogenic contribution to crucial cellular functioning, an elaborate genetic, structural, and functional map of Ras is being created for its therapeutic targeting. Despite decades of research, there still exist lacunae in our understanding of Ras. The complexity of the Ras functioning is further exemplified by the fact...
Source
Around 20% of all malignancies harbour activating mutations in RAS isoforms. Despite this, there is a deficiency of RAS-targeting agents licensed for therapeutic use. The picomolar affinity of RAS for GTP, and the lack of suitable pockets for high-affinity small-molecule binding, precluded effective therapies despite decades of research. Recently, characterisation of the biochemical properties of KRAS-G12C along with discovery of its ‘switch-II pocket’ have allowed development of effective mutan...
Source
The discovery and clinical validation of biomarkers predictive of the response of non-squamous non-small-cell lung carcinomas (NS-NSCLC) to therapeutic strategies continue to provide new data. The evaluation of novel treatments is based on molecular analyses aimed at determining their efficacy. These tests are increasing in number, but the tissue specimens are smaller and smaller and/or can have few tumor cells. Indeed, in addition to tissue samples, complementary cytological and/or blood sample...
Source